J. Claude Bennett, M.D., President and Chief Operating Officer of BioCryst, Honored by American College of Rheumatology.BIRMINGHAM, Ala.--(BW HealthWire)--November 12, 1998--BioCryst Pharmaceuticals, Inc. (Nasdaq NM: BCRX) today announced that J. Claude Bennett, M.D., President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of BioCryst, was recognized by the American College of Rheumatology (ACR) as one of the 1998 Masters of the College. The award was presented at the 62nd annual meeting in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. yesterday. Recognition as a Master of the College of Rheumatology is one of the highest honors that the ACR can present to a member. The distinction is bestowed upon members of the ACR who have set the highest professional standards in advancing the art and science of rheumatology. Dr. Bennett and eleven others received the honor this year, bringing the total number of Masters to 104. A nationally recognized academician and clinical researcher, Dr. Bennett came to BioCryst at the end of 1996 with more than 35 years of research, medical and executive experience. Prior to assuming the role of President/COO of BioCryst, Dr. Bennett served as President of the University of Alabama at Birmingham UAB began in 1936 as the Birmingham Extension Center of the University of Alabama. Because of the rapid growth of the Birmingham area, it was decided that an extension program for students who had difficulties which prevented them from studying in Tuscaloosa was needed. (UAB) and Professor and Chairman of the University's Department of Medicine from 1982 to 1993. Dr. Bennett earned his medical degree from Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. and his undergraduate degree from Samford University in Birmingham, Alabama. In addition, Dr. Bennett did postdoctoral work in medicine, immunology, rheumatology and molecular biology at the University of Alabama The University of Alabama (also known as Alabama, UA or colloquially as 'Bama) is a public coeducational university located in Tuscaloosa, Alabama, USA. Founded in 1831, UA is the flagship campus of the University of Alabama System. Hospital, Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world , National Institutes of Health, and California Institute of Technology California Institute of Technology, at Pasadena, Calif.; originally for men, became coeducational in 1970; founded 1891 as Throop Polytechnic Institute; called Throop College of Technology, 1913–20. . He joined UAB as an Assistant Professor in the Department of Medicine in 1965. During his career, Dr. Bennett has published more than 225 articles, abstracts and editorials. Currently, he is the senior co-editor of the Cecil Textbook of Medicine. Founded in 1986, BioCryst Pharmaceuticals, Inc. designs and develops novel small-molecule pharmaceuticals using structure-based drug design, an approach to drug discovery that integrates advanced biology, biophysics and medicinal chemistry. BioCryst is in clinical trials with its purine nucleoside phosphorylase inhibitor drug candidate, BCX-34, for T-cell related disorders such as psoriasis, cutaneous T-cell lymphoma Cutaneous T-Cell Lymphoma Definition Cutaneous T-cell lymphoma (CTCL) is a malignancy of the T-helper (CD4+) cells of the immune system. Description and HIV. Additionally, the Company's serine protease inhibitor drug candidate, BCX-1470, designed to inhibit activation of the complement pathway, is in initial clinical trials. BioCryst also has a preclinical development program with drugs designed to inhibit the influenza neuraminidase neuraminidase /neu·ra·min·i·dase/ (-ah-min´i-das) an enzyme of the surface coat of myxoviruses that destroys the neuraminic acid of the cell surface during attachment, thereby preventing hemagglutination. enzyme associated with flu infection. This press release contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are only predictions and the actual events or results may differ materially. Please refer to the documents BioCryst files from time to time with the Securities and Exchange Commission, specifically BioCryst's most recent Form 10-K and Form 10-Q. These documents contain and identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion